Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-04-28 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "云南生物谷药业股份有限公司 2024 年第一季度报告" which translates to "Yunnan Biovalley Pharmaceutical Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and explanations of significant changes in financial data. The report covers the period ending March 31, 2024, which is a quarterly period. It explicitly states that the report is unaudited and includes management's responsibility statements. The content includes comprehensive financial figures, shareholder information, litigation updates, and other operational details typical of an interim or quarterly financial report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-28 Chinese
2023年度独立董事述职报告（黎超波）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2023 by an independent director of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the director's duties, attendance at meetings, opinions expressed, communication with auditors, and other supervisory activities during the year. The content focuses on governance, oversight, and compliance with laws and regulations, rather than financial results or audit opinions alone. It is a detailed report on board/management activities and governance practices, specifically from the perspective of an independent director's role and responsibilities. It is not an annual report, audit report, earnings release, or any other financial statement. It is also not a brief announcement or a proxy solicitation. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 4234 characters, which is sufficient for a detailed report rather than a short announcement.
2024-04-28 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2023' which translates to 'Annual Report 2023'. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management information, industry information, corporate governance, internal control, investor protection, and financial accounting reports. The document includes comprehensive financial data for the fiscal year 2023, including income, profit, asset and liability structure, quarterly financial data, and non-recurring gains and losses. It also contains management's discussion and analysis of business operations, industry conditions, and financial analysis. The presence of an auditor's report with a qualified opinion is mentioned, which is typical in annual reports. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-28 Chinese
关于2023年度权益分派的说明
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Yunnan Biovalley Pharmaceutical Co., Ltd. regarding the 2023 annual profit distribution plan. It states that due to a net loss in 2023 and a qualified audit opinion, no cash dividends, bonus shares, or capital reserve transfers will be made. The document includes details of board and supervisory committee meetings approving the proposal, which still requires shareholder approval at the 2023 annual general meeting. The document is short (1329 characters) and primarily communicates the dividend distribution decision and related meeting resolutions. It does not contain full financial statements or comprehensive financial performance data. Therefore, it is not an Annual Report (10-K) or Interim Report (IR), but rather a Notice of Dividend Amount (DIV) announcement explaining the dividend policy for the year.
2024-04-28 Chinese
2023年度独立董事述职报告（张倩芸）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2023 from Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the independent director's duties, attendance at meetings, opinions on various board matters, communication with auditors, and training activities. The content focuses on governance, oversight, and compliance with regulatory requirements rather than financial results or audit opinions. It is not a full annual report, audit report, or earnings release. It is a detailed report related to board/management activities and governance oversight by an independent director. Therefore, the document best fits the category of Board/Management Information (MANG). The document length is 4243 characters, which is substantive and contains detailed information about board activities and management oversight, supporting a high confidence classification.
2024-04-28 Chinese
董事会审计委员会2023年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report on the 2023 annual performance of the Board Audit Committee of Yunnan Biovalley Pharmaceutical Co., Ltd. It details the committee's composition, meetings held, work performed including oversight of external audits, review of financial reports, internal audit guidance, and coordination with management and auditors. The document is a detailed report on the audit committee's activities and their evaluation of the company's audit and financial reporting processes for the year 2023. It is not an audit report itself, nor a full annual report, but a specific committee report on audit-related governance and oversight activities. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related information about audit committee activities and applied accounting principles, excluding full annual reports. The document length is 2803 characters, which is sufficient for a detailed committee report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2023
2024-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.